Skip to main content

Our mission

We create inspired medicines that matter to cancer patients based on our expertise and ADC technologies

ADC Drug Development

We use the active ingredient Amanitin from the death cap mushroom for cancer therapies by researching, producing and clinically developing so-called Antibody Amanitin Conjugates.

ATACs belong to the class of Antibody Drug Conjugates (ADCs), which combine the high affinity and specificity of antibodies with the efficacy of small toxic molecules to fight cancer.

News

PR: Heidelberg Pharma Announces Changes to the Executive Management Board
29 November 2023
Open
AH: Heidelberg Pharma Announces Changes to the Executive Management Board
29 November 2023
Open
PR: Heidelberg Pharma Secures Patent for the Use of its ADC Technology Platform
15 November 2023
Open
PR: Heidelberg Pharma Presents New Clinical Data from its Lead Candidate HDP-101 at the ASH Annual Meeting 2023
02 November 2023
Open

Meet us

17th Annual European Life Science CEO Forum
28. - 29. Februar 2024
World ADC
12. - 15. März
AACR Annual Meeting 2024
5. - 10. April

Partner Information

TitleDate
Telix: Telix Submits Biologics License Application (BLA) for TLX250-CDx (Zircaix™) for Imaging of Kidney Cancer
19 December 2023
Read more
Telix: First Patient Dosed in U.S. Expanded Access Program for TLX250-CDx, Telix’s Breakthrough Kidney Cancer Imaging Agent
11 December 2023
Read more
Telix: Positive Topline Results from Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer Presented at SABCS
7 December 2023
Read more
Telix: First Patient Dosed in European Named Patient (Early Access) Program for TLX250-CDx, Telix’s Kidney Cancer Imaging Agent
4 December2023
Read more
Telix: Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS
30 November 2023
Read more